Survivin-3B gene decreases the invasion-inhibitory effect of colon cancer cells with 5-fluorouracil

Oncology Research

Volumn 18, Issue 11-12, 2010, Pages 541-547

  Sawai, Katsuji ^a   Goi, Takanori ^a   Hirono, Yasuo ^a   Katayama, Kanji ^a   Yamaguchi, Akio ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Colon cancer; Invasion; Survivin 3B

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; BIRC5 PROTEIN, HUMAN; FLUOROURACIL; INHIBITOR OF APOPTOSIS PROTEIN; MICROTUBULE ASSOCIATED PROTEIN;

COLON TUMOR; GENETICS; HUMAN; MORTALITY; PATHOLOGY; SURVIVAL RATE; TUMOR CELL LINE; TUMOR INVASION;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; COLONIC NEOPLASMS; FLUOROURACIL; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM INVASIVENESS; SURVIVAL RATE;

EID: 77956895535     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504010X12767359113848     Document Type: Article

References (47)

1. Jin, Z.; El-Deiry, W. S. Overview of cell death signaling pathways. Cancer Biol. Ther. 4:139-163; 2005.
2. Vermeulen, K.; Van Bockstaele, D. R.; Berneman, Z. N. Apoptosis: Mechanisms and relevance in cancer. Ann. Hematol. 84:627-639; 2005.
3. Gupta, S. Molecular steps of death receptor and mitochondrial pathways of apoptosis. Life Sci. 69:2957-2964; 2001. (Pubitemid 33044692)
4. Schimmer, A. D. Inhibitor of apoptosis proteins: Translating basic knowledge into clinical practice. Cancer Res. 64: 7183-7190; 2004.
5. Yang, Y. L.; Li, X. M. The IAP family: Endogenous caspase inhibitors with multiple biological activities. Cell Res. 10:169-177; 2000.
6. Dubrez-Daloz, L.; Dupoux, A.; Cartier, J. IAPs: More than just inhibitors of apoptosis proteins. Cell Cycle 7: 1036-1046; 2008.
7. LaCasse, E. C.; Mahoney, D. J.; Cheung, H. H.; Plenchette, S.; Baird, S.; Korneluk, R. G. IAP-targeted therapies for cancer. Oncogene 27:6252-6275; 2008.
8. Zangemeister-Wittke, U.; Simon, H. U. An IAP in action: The multiple roles of survivin in differentiation, immunity and malignancy. Cell Cycle 3:1121-1123; 2004.
9. Tamm, I.; Wang, Y.; Sausville, E.; Scudiero, D. A.; Vigna, N.; Oltersdorf, T.; Reed, J. C. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58:5315-5320; 1998.
10. Chandele, A.; Prasad, V.; Jagtap, J. C.; Shukla, R.; Shastry, P. R. Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia 6:29-40; 2004.
11. Mahotka, C.; Wenzel, M.; Springer, E.; Gabbert, H. E.; Gerharz, C. D. Survivin-deltaEx3 and survivin-2B: Two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 59: 6097-6102; 1999.
12. Badran, A.; Yoshida, A.; Ishikawa, K.; Goi, T.; Yamaguchi, A.; Ueda, T.; Inuzuka, M. Identification of a novel splice variant of the human anti-apoptopsis gene surviving. Biochem. Biophys. Res. Commun. 314:902-907; 2004.
13. Fleming, I. D.; Cooper, J. S.; Fleming, I. D.; Cooper, J. S.; Murphy, G. P.; Sullivan, B. O.; Sobin, L. H.; Yarbro, J. W. AJCC cancer staging manual, 5th ed. Philadelphia: Lippincott-Raven; 1997.
14. Japanese Society for Cancer of the Colon and Rectum. Japanese classification of colorectal carcinoma, 1st English edition. Tokyo: Kanehara; 1997.
15. Goi, T.; Yamaguchi, A.; Nakagawara, G.; Urano, T.; Shiku, H.; Furukawa, K. Reduced expression of deleted colorectal carcinoma (DCC) protein in established colon cancers. Br. J. Cancer 77:466-471; 1998.
16. Sato, T.; Yamaguchi, A.; Goi, T.; Hirono, Y.; Takeuchi, K.; Katayama, K.; Matsukawa, S. Heparanase expression in human colorectal cancer and its relationship to tumor angiogenesis, hematogenous metastasis, and prognosis. J. Surg. Oncol. 87:174-181; 2004.
17. Savill, J.; Fadok, V. Corpse clearance defines the meaning of cell death. Nature 407:784-788; 2000.
18. Lowe, S. W.; Lin, A. W. Apoptosis in cancer. Carcinogenesis 21:485-495; 2000.
19. Hengartner, M. O. The biochemistry of apoptosis. Nature 407:770-776; 2000.
20. Thompson, C. B. Apoptosis in the pathogenesis and treatment of disease. Science 267:1456-1462; 1995.
21. Berglund, H.; Olerenshaw, D.; Sankar, A.; Federwisch, M.; McDonald, N. Q.; Driscoll, P. C. The three-dimensional solution structure and dynamic properties of the human FADD death domain. J. Mol. Biol. 302:171-188; 2000.
22. Kang, J.; Schaber, M. D.; Srinivasula, S.; Alnemri, E. S.; Litwack, G.; Hall, D. J.; Bjornsti, M. A. Cascades of mammalian caspase activation in the yeast Saccharomyces cerevisiae. J. Biol. Chem. 274:3189-3198; 1999.
23. Kluck, R. M.; Bossy-Wetzel, E.; Green, D. R.; Newmeyer, D. D. The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science 275:1132-1136; 1997.
24. Saleh, A.; Srinivasula, S.; Acharya, S.; Fishel, R.; Alnemri, E. Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. J. Biol. Chem. 274:17941-17945; 1999.
25. Zou, H.; Henzel, W. J.; Liu, X.; Lutschg, A.; Wang, X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90:405-413; 1997.
26. Marusawa, H.; Matsuzawa, S.; Welsh, K.; Zou, H.; Armstrong, R.; Tamm, I.; Reed, J. C. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J. 22:2729-2740; 2003.
27. Chen, W. C.; Liu, Q.; Fu, J. X.; Kang, S. Y. Expression of survivin and its significance in colorectal cancer. World J. Gastroenterol. 10:2886-2889; 2004.
28. Lam, A. K.; Saleh, S.; Smith, R. A.; Ho, Y. H. Quantitative analysis of survivin in colorectal adenocarcinoma: Increased expression and correlation with telomerase activity. Hum. Pathol. 39:1229-1233; 2008.
29. Lee, G. H.; Joo, Y. E.; Koh, Y. S.; Chung, I. J.; Park, Y. K.; Lee, J. H.; Kim, H. S.; Choi, S. K.; Rew, J. S.; Park, C. S.; Kim, S. J. Expression of survivin in gastric cancer and its relationship with tumor angiogenesis. Eur. J. Gastroenterol. Hepatol. 18:957-963; 2006.
30. Miyachi, K.; Sasaki, K.; Onodera, S.; Taguchi, T.; Nagamachi, M.; Kaneko, H.; Sunagawa, M. Correlation between survivin mRNA expression and lymph node metastasis in gastric cancer. Gastric Cancer 6:217-224; 2003. (Pubitemid 38140003)
31. Kania, J.; Konturek, S. J.; Marlicz, K.; Hahn, E. G.; Konturek, P. C. Expression of survivin and caspase-3 in gastric cancer. Dig. Dis. Sci. 48:266-271; 2003.
32. Sarela, A. I.; Scott, N.; Ramsdale, J.; Markham, A. F.; Guillou, P. J. Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann. Surg. Oncol. 8:305-310; 2001.
33. Kim, P. J.; Plescia, J.; Clevers, H.; Fearon, E. R.; Altieri, D. C. Survivin and molecular pathogenesis of colorectal cancer. Lancet 362:205-209; 2003.
34. Kawasaki, H.; Altieri, D. C.; Lu, C. D.; Toyoda, M.; Tenjo, T.; Tanigawa, N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 58:5071-5074; 1998. (Pubitemid 28521163)
35. Knutsen, A.; Adell, G.; Sun, X. F. Survivin expression is an independent prognostic factor in rectal cancer patients with and without preoperative radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 60:149-155; 2004.
36. Rödel, F.; Hoffmann, J.; Grabenbauer, G. G.; Papadopoulos, T.; Weiss, C.; Günther, K.; Schick, C.; Sauer, R.; Rödel, C. High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol. 178:426-435; 2002.
37. Sarela, A. I.; Macadam, R. C.; Farmery, S. M.; Markham, A. F.; Guillou, P. J. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 46:645-650; 2000.
38. Végran, F.; Boidot, R.; Oudin, C.; Defrain, C.; Rebucci, M.; Lizard-Nacol, S. Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene 26:290-297; 2007. (Pubitemid 46095740)
39. De Maria, S.; Pannone, G.; Bufo, P.; Santoro, A.; Serpico, R.; Metafora, S.; Rubini, C.; Pasquali, D.; Papagerakis, S. M.; Staibano, S.; De Rosa, G.; Farina, E.; Emanuelli, M.; Santarelli, A.; Mariggiò, M. A.; Lo Russo, L.; Lo Muzio, L. Survivin gene-expression and splicing isoforms in oral squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 135:107-116; 2009.
40. Obrand, D. I.; Gordon, P. H. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis. Colon Rectum 40:15-24; 1997.
41. Tominaga, T.; Sakabe, T.; Koyama, Y.; Hamano, K.; Yasutomi, M.; Takahashi, T.; Kodaira, S.; Kato, T.; Ogawa, N. Prognostic factors for patients with colon or rectal carcinoma treated with resection only. Five-year follow-up report. Cancer 78:403-408; 1996.
42. Goi, T.; Obata, S.; Inoue, T.; Fujioka, M.; Hirono, Y.; Katayama, K.; Yamaguchi, A. Clinicopathological study of the colorectal mucinous carcinomas. Int. Surg. 91:352-357; 2006.
43. Goi, T.; Hirono, Y.; Katayama, K.; Yamaguchi, A. Microsatellite instability and survival rate in the solid or non-solid types of poorly differentiated colorectal adenocarcinoma. Int. Surg. 89:100-106; 2004.
44. Ueno, H.; Mochizuki, H.; Hashiguchi, Y.; Shimazaki, H.; Aida, S.; Hase, K.; Matsukuma, S.; Kanai, T.; Kurihara, H.; Ozawa, K.; Yoshimura, K.; Bekku, S. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 127:385-394; 2004.
45. Katayama, K.; Yamaguchi, A.; Murakami, M.; Koneri, K.; Nagano, H.; Honda, K.; Hirono, Y.; Goi, T.; Iida, A.; Ito, H. Chemo-hyperthermic peritoneal perfusion (CHPP) for appendiceal pseudomyxoma peritonei. Int. J. Clin. Oncol. 14:120-124; 2009.
46. Fuchs, C. S.; Marshall, J.; Barrueco, J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Updated results from the BICC-C study. J. Clin. Oncol. 26:689-690; 2008.
47. Sobrero, A. F.; Maurel, J.; Fehrenbacher, L.; Scheithauer, W.; Abubakr, Y. A.; Lutz, M. P.; Vega-Villegas, M. E.; Eng, C.; Steinhauer, E. U.; Prausova, J.; Lenz, H. J.; Borg, C.; Middleton, G.; Kröning, H.; Luppi, G.; Kisker, O.; Zubel, A.; Langer, C.; Kopit, J.; Burris, 3rd, H. A. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 26:2311-2319; 2008.